{
    "protocolSection": {
        "identificationModule": {
            "nctId": "NCT05668585",
            "orgStudyIdInfo": {
                "id": "CFT1946-1101"
            },
            "organization": {
                "fullName": "C4 Therapeutics, Inc.",
                "class": "INDUSTRY"
            },
            "briefTitle": "A Study to Characterize the Safety, Tolerability, and Preliminary Efficacy of CFT1946 as Monotherapy and Combination Therapy in Subjects With BRAF V600 Mutant Solid Tumors",
            "officialTitle": "A Phase 1/2 Open-Label Multicenter Trial to Characterize the Safety, Tolerability, and Preliminary Efficacy of CFT1946 as Monotherapy and Combination Therapy in Subjects With BRAF V600 Mutant Solid Tumors",
            "therapeuticArea": [
                "Oncology and Hematology",
                "Other"
            ],
            "study": "a-study-to-characterize-the-safety-tolerability-and-preliminary-efficacy-of-as-monotherapy-and-combination-therapy-in-subjects-with-braf-mutant-solid-tumors"
        },
        "statusModule": {
            "statusVerifiedDate": "2024-07",
            "overallStatus": "RECRUITING",
            "expandedAccessInfo": {
                "hasExpandedAccess": false
            },
            "startDateStruct": {
                "date": "2022-12-08",
                "type": "ACTUAL"
            },
            "primaryCompletionDateStruct": {
                "date": "2027-03-11",
                "type": "ESTIMATED"
            },
            "completionDateStruct": {
                "date": "2027-04-11",
                "type": "ESTIMATED"
            },
            "studyFirstSubmitDate": "2022-12-06",
            "studyFirstSubmitQcDate": "2022-12-19",
            "studyFirstPostDateStruct": {
                "date": "2022-12-30",
                "type": "ACTUAL"
            },
            "lastUpdateSubmitDate": "2024-07-17",
            "lastUpdatePostDateStruct": {
                "date": "2024-07-18",
                "type": "ACTUAL"
            }
        },
        "sponsorCollaboratorsModule": {
            "responsibleParty": {
                "type": "SPONSOR"
            },
            "leadSponsor": {
                "name": "C4 Therapeutics, Inc.",
                "class": "INDUSTRY"
            }
        },
        "oversightModule": {
            "oversightHasDmc": false,
            "isFdaRegulatedDrug": true,
            "isFdaRegulatedDevice": false
        },
        "descriptionModule": {
            "briefSummary": "The purpose of this study is to evaluate the safety and tolerability of CFT1946 as well as to determine the maximum tolerated dose (MTD) and/or the recommended Phase 2 dose (RP2D) of CFT1946 as monotherapy (Arm A) and in combination with trametinib (CFT1946 + trametinib; Arm B) or Cetuximab (CFT1946 + cetuximab; Arm C)."
        },
        "conditionsModule": {
            "conditions": [
                "Solid Tumors",
                "Melanoma",
                "NSCLC",
                "CRC",
                "ATC"
            ],
            "keywords": [
                "Solid Tumors",
                "Melanoma",
                "NSCLC",
                "ATC",
                "BRAF mutant",
                "CRC"
            ]
        },
        "designModule": {
            "studyType": "INTERVENTIONAL",
            "phases": [
                "PHASE1",
                "PHASE2"
            ],
            "designInfo": {
                "allocation": "NON_RANDOMIZED",
                "interventionModel": "SEQUENTIAL",
                "primaryPurpose": "TREATMENT",
                "maskingInfo": {
                    "masking": "NONE"
                }
            },
            "enrollmentInfo": {
                "count": 206,
                "type": "ESTIMATED"
            }
        },
        "armsInterventionsModule": {
            "armGroups": [
                {
                    "label": "Phase 1: Arm A: CFT1946",
                    "type": "EXPERIMENTAL",
                    "description": "Approximately 40 subjects with V600 Solid Tumors (non-CNS) (post BRAF inhibitor for NSCLC, CRC, melanoma, ATC)",
                    "interventionNames": [
                        "Drug: CFT1946"
                    ]
                },
                {
                    "label": "Phase 1: Arm B: CFT1946 + trametinib",
                    "type": "EXPERIMENTAL",
                    "description": "Approximately 28 subjects with V600 Solid Tumors (non-CNS) (post BRAF inhibitor for NSCLC, CRC, melanoma)",
                    "interventionNames": [
                        "Drug: CFT1946",
                        "Drug: Trametinib"
                    ]
                },
                {
                    "label": "Phase 2: Arm A1: CFT1946",
                    "type": "EXPERIMENTAL",
                    "description": "Approximately 30 subjects with V600 melanoma or NSCLC (post BRAF inhibitor)",
                    "interventionNames": [
                        "Drug: CFT1946"
                    ]
                },
                {
                    "label": "Phase 2: Arm B1: CFT1946 + trametinib",
                    "type": "EXPERIMENTAL",
                    "description": "Approximately 20 subjects with V600 melanoma or NSCLC (post BRAF Inhibitor)",
                    "interventionNames": [
                        "Drug: CFT1946",
                        "Drug: Trametinib"
                    ]
                },
                {
                    "label": "Phase 1: Arm C: CFT1946 + cetuximab",
                    "type": "EXPERIMENTAL",
                    "description": "Approximately 30 subjects with CRC (post BRAF inhibitor)",
                    "interventionNames": [
                        "Drug: CFT1946",
                        "Drug: Cetuximab"
                    ]
                },
                {
                    "label": "Phase 2: Arm C1: CFT1946 + cetuximab",
                    "type": "EXPERIMENTAL",
                    "description": "Approximately 40 subjects with CRC (post BRAF inhibitor)",
                    "interventionNames": [
                        "Drug: CFT1946",
                        "Drug: Cetuximab"
                    ]
                }
            ],
            "interventions": [
                {
                    "type": "DRUG",
                    "name": "CFT1946",
                    "description": "Specified oral dose on specified day",
                    "armGroupLabels": [
                        "Phase 1: Arm A: CFT1946",
                        "Phase 1: Arm B: CFT1946 + trametinib",
                        "Phase 1: Arm C: CFT1946 + cetuximab",
                        "Phase 2: Arm A1: CFT1946",
                        "Phase 2: Arm B1: CFT1946 + trametinib",
                        "Phase 2: Arm C1: CFT1946 + cetuximab"
                    ]
                },
                {
                    "type": "DRUG",
                    "name": "Trametinib",
                    "description": "Specified oral dose on specified day",
                    "armGroupLabels": [
                        "Phase 1: Arm B: CFT1946 + trametinib",
                        "Phase 2: Arm B1: CFT1946 + trametinib"
                    ]
                },
                {
                    "type": "DRUG",
                    "name": "Cetuximab",
                    "description": "Specified intravenous dose on specified day",
                    "armGroupLabels": [
                        "Phase 1: Arm C: CFT1946 + cetuximab",
                        "Phase 2: Arm C1: CFT1946 + cetuximab"
                    ]
                }
            ]
        },
        "outcomesModule": {
            "primaryOutcomes": [
                {
                    "measure": "Frequency and severity of AEs and SAEs",
                    "description": "Phase 1",
                    "timeFrame": "From enrollment until 30 days after completion of study treatment"
                },
                {
                    "measure": "Incidence of dose limiting toxicities (DLTs)",
                    "description": "Phase 1",
                    "timeFrame": "From enrollment until 28 days after first dose"
                },
                {
                    "measure": "Number of subjects with changes between baseline and post-baseline safety assessments based on safety laboratory results graded by CTCAE v5.0",
                    "description": "Phase 1",
                    "timeFrame": "From enrollment until 30 days after completion of study treatment"
                },
                {
                    "measure": "Frequency of dose interruptions and dose reductions",
                    "description": "Phase 1",
                    "timeFrame": "From enrollment until 30 days after completion of study treatment"
                },
                {
                    "measure": "Frequency of AEs leading to discontinuation of study treatment(s)",
                    "description": "Phase 1",
                    "timeFrame": "From enrollment until 30 days after completion of study treatment"
                },
                {
                    "measure": "Overall response rate (ORR)",
                    "description": "Phase 2 only according to RECIST v1.1 criteria",
                    "timeFrame": "Up to approximately 43 months"
                },
                {
                    "measure": "Disease control rate (DCR) at 3, 6, and 12 months",
                    "description": "Phase 2",
                    "timeFrame": "Up to 12 months"
                },
                {
                    "measure": "Duration of Response (DOR)",
                    "description": "Phase 2",
                    "timeFrame": "Up to approximately 43 months"
                }
            ],
            "secondaryOutcomes": [
                {
                    "measure": "Frequency and severity of AEs and SAEs",
                    "description": "Phase 2",
                    "timeFrame": "From enrollment until 30 days after completion of study treatment"
                },
                {
                    "measure": "Number of subjects with changes between baseline and post-baseline safety assessments based on safety laboratory results graded by CTCAE v5.0",
                    "description": "Phase 2",
                    "timeFrame": "From enrollment until 30 days after completion of study treatment"
                },
                {
                    "measure": "Frequency of dose interruptions and dose reductions",
                    "description": "Phase 2",
                    "timeFrame": "From enrollment until 30 days after completion of study treatment"
                },
                {
                    "measure": "Frequency of AEs leading to discontinuation of study treatment(s)",
                    "description": "Phase 2",
                    "timeFrame": "From enrollment until 30 days after completion of study treatment"
                },
                {
                    "measure": "Plasma concentration of CFT1946 to characterize the pharmacokinetics (PK) parameters of CFT1946 monotherapy and in combination with trametinib",
                    "description": "Phase 1 and Phase 2",
                    "timeFrame": "Up to approximately 20 weeks"
                },
                {
                    "measure": "PK-QTcF relationship",
                    "description": "Phase 1 and Phase 2",
                    "timeFrame": "Up to approximately 8 weeks"
                },
                {
                    "measure": "Overall response rate (ORR)",
                    "description": "Phase 1",
                    "timeFrame": "Up to approximately 43 months"
                },
                {
                    "measure": "Disease control rate (DCR) at 3, 6, and 12 months",
                    "description": "Phase 1",
                    "timeFrame": "Up to 12 months"
                },
                {
                    "measure": "Progression-free survival (PFS)",
                    "description": "Phase 1 and Phase 2",
                    "timeFrame": "Up to approximately 43 months"
                },
                {
                    "measure": "Duration of response (DOR)",
                    "description": "Phase 1",
                    "timeFrame": "Up to approximately 43 months"
                },
                {
                    "measure": "Assess the pharmacodynamics by percent reduction from baseline of target protein",
                    "description": "Tumor BRAF-V600 degradation at scheduled timepoints",
                    "timeFrame": "At multiple time points up to 4 weeks"
                }
            ]
        },
        "eligibilityModule": {
            "eligibilityCriteria": "Inclusion Criteria:\n\n1. Subject (or legally authorized representative, where applicable) is willing and able to provide signed informed consent and can follow protocol requirements\n2. Subject is \u226518 years of age at time of informed consent\n3. Eastern Cooperative Oncology Group performance status of 0 or 1\n4. Subject has documented evidence of a BRAF V600 mutation obtained from tumor tissue or liquid biopsy: (other protocol conditions may apply)\n5. Subject must have received \u22651 prior line of SoC therapy for their unresectable locally advanced or metastatic disease with disease progression on or after last prior treatment. Prior regimens for these subjects vary by indication and investigational arm, but must have included the following:\n\n   1. Melanoma or NSCLC (Phase 1 and Phase 2 Arms A1 and B1): Prior receipt of a BRAF inhibitor and an immune checkpoint inhibitor (any sequence or combination). Prior (neo)adjuvant immunotherapy may be acceptable.\n   2. CRC: Subjects must have received no more than 4 lines of prior therapy which includes systemic chemotherapy-based regimen per SoC for unresectable locally advanced or metastatic disease, and previous treatment with BRAF inhibitor in combination with an EGFR monoclonal antibody. Subjects with documented MSI-H or dMMR CRC must have received prior immunotherapy. Subjects with MSS disease must have received at least 2 prior treatments. Subjects who received neo(adjuvant) chemotherapy regimens may be eligible.\n   3. ATC: Subjects must have received SoC therapy options including BRAF inhibitor if available and of benefit to the subject\n   4. Other BRAF V600 mutant solid tumors (non-CNS): Subjects must have received SoC therapy options per their Investigator's best judgment, including BRAF inhibitor if available and of benefit to the subject\n6. Subject has measurable disease per RECIST v1.1\n7. Adequate bone marrow, liver, renal, and cardiac function\n8. A female subject may be eligible if not pregnant, planning a pregnancy, not breast feeding, a women of non-child bearing potential or a WOCBP willing to comply with protocol conditions relating to the use contraception, ova or blood donation and pregnancy testing prior to the first dose\n9. A male subject must agree to comply with protocol conditions relating to the use of contraception, sperm and blood donation\n10. Subject can safely swallow a tablet or pill\n\nOther protocol defined exclusion criteria may apply\n\nExclusion Criteria:\n\n1. Subject has had major surgery within 21 days prior to the planned first dose. Minor surgery is permitted within 21 days prior to enrollment\n2. Subject with CNS involvement (primary tumor or metastatic disease), except if clinically stable, have no evidence of new or enlarging brain metastases and are on stable or tapering doses of steroids for at least 7 days prior to first dose. Subjects with untreated brain metastases may be eligible to enter without prior radiation therapy.\n3. Subject with known malignancy other than trial indication that is progressing or has required treatment within the past 3 years, except for conditions that have undergone potentially curative therapy\n4. Subject with history of thromboembolic or cerebrovascular events \u22646 months as defined in the protocol\n5. Subject with impaired cardiac function or clinically significant cardiac disease, as defined in the protocol\n6. Subject with history of uncontrolled diabetes mellitus (only for subjects who will receive CFT1946 + trametinib)\n7. Subject with history or current evidence of retinal vein occlusion (RVO), chorioretinopathy, or current risk factors for RVO (only for subjects who will receive CFT1946 + trametinib)\n8. Subject has received live, attenuated vaccine within 28 days prior to first dose administration\n9. Subject has history of pneumonitis or interstitial lung disease\n10. Subject has history of uveitis\n11. Subject has clinically significant gastrointestinal abnormalities.\n12. Subject has known human immunodeficiency virus (HIV) infection (with exceptions)\n13. Subject has history of or known HBV or active HCV infection\n14. Subject has concurrent administration of strong CYP3A4/5 inhibitors and inducers, including any herbal medications/supplements\n15. Subject has presence of Grade \u22652 toxicity due to prior cancer therapy, excepting alopecia and hypothyroidism requiring thyroid replacement therapy\n16. Subject has initiation or receipt of the following \u22647 days prior to first dose administration: Hematopoietic colony-stimulating growth factors, transfusion of packed red blood cells (pRBC), and transfusion of platelets\n17. Subject is pregnant, breastfeeding, or expecting to conceive or father children any time during the study\n\nOther protocol defined exclusion criteria may apply",
            "healthyVolunteers": false,
            "sex": "ALL",
            "minimumAge": "18 Years",
            "stdAges": [
                "ADULT",
                "OLDER_ADULT"
            ]
        },
        "contactsLocationsModule": {
            "centralContacts": [
                {
                    "name": "Study Medical Officer",
                    "role": "CONTACT",
                    "phone": "(617) 231-0700",
                    "email": "clinicaltrials@c4therapeutics.com"
                }
            ],
            "locations": [
                {
                    "facility": "Florida Cancer Specialists",
                    "status": "RECRUITING",
                    "city": "Sarasota",
                    "state": "Florida",
                    "zip": "34232",
                    "country": "United States",
                    "geoPoint": {
                        "lat": 27.33643,
                        "lon": -82.53065
                    }
                },
                {
                    "facility": "Dana-Farber Cancer Institute",
                    "status": "RECRUITING",
                    "city": "Boston",
                    "state": "Massachusetts",
                    "zip": "02215",
                    "country": "United States",
                    "geoPoint": {
                        "lat": 42.35843,
                        "lon": -71.05977
                    }
                },
                {
                    "facility": "Washington University School of Medicine",
                    "status": "RECRUITING",
                    "city": "Saint Louis",
                    "state": "Missouri",
                    "zip": "63110",
                    "country": "United States",
                    "geoPoint": {
                        "lat": 38.62727,
                        "lon": -90.19789
                    }
                },
                {
                    "facility": "David H. Koch Center for Cancer Care at Memorial Sloan Kettering Cancer Center",
                    "status": "RECRUITING",
                    "city": "New York",
                    "state": "New York",
                    "zip": "10021",
                    "country": "United States",
                    "geoPoint": {
                        "lat": 40.71427,
                        "lon": -74.00597
                    }
                },
                {
                    "facility": "Sarah Cannon and HCA Research Institute",
                    "status": "RECRUITING",
                    "city": "Nashville",
                    "state": "Tennessee",
                    "zip": "37203",
                    "country": "United States",
                    "geoPoint": {
                        "lat": 36.16589,
                        "lon": -86.78444
                    }
                },
                {
                    "facility": "MD Anderson Cancer Center",
                    "status": "RECRUITING",
                    "city": "Houston",
                    "state": "Texas",
                    "zip": "77030",
                    "country": "United States",
                    "geoPoint": {
                        "lat": 29.76328,
                        "lon": -95.36327
                    }
                },
                {
                    "facility": "Virginia Cancer Specialists (NEXT Oncology Virginia)",
                    "status": "RECRUITING",
                    "city": "Fairfax",
                    "state": "Virginia",
                    "zip": "22031",
                    "country": "United States",
                    "geoPoint": {
                        "lat": 38.84622,
                        "lon": -77.30637
                    }
                },
                {
                    "facility": "University of Wisconsin",
                    "status": "RECRUITING",
                    "city": "Madison",
                    "state": "Wisconsin",
                    "zip": "53792",
                    "country": "United States",
                    "geoPoint": {
                        "lat": 43.07305,
                        "lon": -89.40123
                    }
                },
                {
                    "facility": "Institut Bergonie",
                    "status": "RECRUITING",
                    "city": "Bordeaux Cedex",
                    "zip": "33076",
                    "country": "France",
                    "geoPoint": {
                        "lat": 44.84044,
                        "lon": -0.5805
                    }
                },
                {
                    "facility": "Chu de Lille",
                    "status": "RECRUITING",
                    "city": "Lille",
                    "zip": "59037",
                    "country": "France",
                    "geoPoint": {
                        "lat": 50.63297,
                        "lon": 3.05858
                    }
                },
                {
                    "facility": "Centre Leon Berard",
                    "status": "RECRUITING",
                    "city": "Lyon",
                    "zip": "69008",
                    "country": "France",
                    "geoPoint": {
                        "lat": 45.74848,
                        "lon": 4.84669
                    }
                },
                {
                    "facility": "IUCT Oncopole",
                    "status": "RECRUITING",
                    "city": "Toulouse",
                    "zip": "31059",
                    "country": "France",
                    "geoPoint": {
                        "lat": 43.60426,
                        "lon": 1.44367
                    }
                },
                {
                    "facility": "NEXT Oncology Barcelona",
                    "status": "RECRUITING",
                    "city": "Barcelona",
                    "zip": "08023",
                    "country": "Spain",
                    "geoPoint": {
                        "lat": 41.38879,
                        "lon": 2.15899
                    }
                },
                {
                    "facility": "Hospital Universitario Vall d'Hebron",
                    "status": "RECRUITING",
                    "city": "Barcelona",
                    "zip": "08035",
                    "country": "Spain",
                    "geoPoint": {
                        "lat": 41.38879,
                        "lon": 2.15899
                    }
                },
                {
                    "facility": "South Texas Accelerated Research Therapeutics (START) Madrid - Hospital Fundacion Jiminez Diaz",
                    "status": "RECRUITING",
                    "city": "Madrid",
                    "zip": "28040",
                    "country": "Spain",
                    "geoPoint": {
                        "lat": 40.4165,
                        "lon": -3.70256
                    }
                },
                {
                    "facility": "Hospital Clinico Universitario de Valencia",
                    "status": "RECRUITING",
                    "city": "Valencia",
                    "zip": "46010",
                    "country": "Spain",
                    "geoPoint": {
                        "lat": 39.46975,
                        "lon": -0.37739
                    }
                }
            ]
        },
        "ipdSharingStatementModule": {
            "ipdSharing": "NO"
        }
    },
    "derivedSection": {
        "miscInfoModule": {
            "versionHolder": "2024-07-30"
        },
        "conditionBrowseModule": {
            "meshes": [
                {
                    "id": "D000008545",
                    "term": "Melanoma"
                }
            ],
            "ancestors": [
                {
                    "id": "D000009369",
                    "term": "Neoplasms"
                },
                {
                    "id": "D000018358",
                    "term": "Neuroendocrine Tumors"
                },
                {
                    "id": "D000017599",
                    "term": "Neuroectodermal Tumors"
                },
                {
                    "id": "D000009373",
                    "term": "Neoplasms, Germ Cell and Embryonal"
                },
                {
                    "id": "D000009370",
                    "term": "Neoplasms by Histologic Type"
                },
                {
                    "id": "D000009380",
                    "term": "Neoplasms, Nerve Tissue"
                },
                {
                    "id": "D000018326",
                    "term": "Nevi and Melanomas"
                },
                {
                    "id": "D000012878",
                    "term": "Skin Neoplasms"
                },
                {
                    "id": "D000009371",
                    "term": "Neoplasms by Site"
                },
                {
                    "id": "D000012871",
                    "term": "Skin Diseases"
                }
            ],
            "browseLeaves": [
                {
                    "id": "M11528",
                    "name": "Melanoma",
                    "asFound": "Melanoma",
                    "relevance": "HIGH"
                },
                {
                    "id": "M20495",
                    "name": "Neuroendocrine Tumors",
                    "relevance": "LOW"
                },
                {
                    "id": "M19845",
                    "name": "Neuroectodermal Tumors",
                    "relevance": "LOW"
                },
                {
                    "id": "M20388",
                    "name": "Neuroectodermal Tumors, Primitive",
                    "relevance": "LOW"
                },
                {
                    "id": "M12318",
                    "name": "Neoplasms, Germ Cell and Embryonal",
                    "relevance": "LOW"
                },
                {
                    "id": "M12315",
                    "name": "Neoplasms by Histologic Type",
                    "relevance": "LOW"
                },
                {
                    "id": "M12325",
                    "name": "Neoplasms, Nerve Tissue",
                    "relevance": "LOW"
                },
                {
                    "id": "M12448",
                    "name": "Nevus, Pigmented",
                    "relevance": "LOW"
                },
                {
                    "id": "M12446",
                    "name": "Nevus",
                    "relevance": "LOW"
                },
                {
                    "id": "M20470",
                    "name": "Nevi and Melanomas",
                    "relevance": "LOW"
                },
                {
                    "id": "M15681",
                    "name": "Skin Neoplasms",
                    "relevance": "LOW"
                },
                {
                    "id": "M15674",
                    "name": "Skin Diseases",
                    "relevance": "LOW"
                },
                {
                    "id": "T4091",
                    "name": "Neuroendocrine Tumor",
                    "relevance": "LOW"
                },
                {
                    "id": "T4092",
                    "name": "Neuroepithelioma",
                    "relevance": "LOW"
                }
            ],
            "browseBranches": [
                {
                    "abbrev": "BC04",
                    "name": "Neoplasms"
                },
                {
                    "abbrev": "BC17",
                    "name": "Skin and Connective Tissue Diseases"
                },
                {
                    "abbrev": "All",
                    "name": "All Conditions"
                },
                {
                    "abbrev": "Rare",
                    "name": "Rare Diseases"
                }
            ]
        },
        "interventionBrowseModule": {
            "meshes": [
                {
                    "id": "D000068818",
                    "term": "Cetuximab"
                },
                {
                    "id": "C000560077",
                    "term": "Trametinib"
                }
            ],
            "ancestors": [
                {
                    "id": "D000074322",
                    "term": "Antineoplastic Agents, Immunological"
                },
                {
                    "id": "D000000970",
                    "term": "Antineoplastic Agents"
                },
                {
                    "id": "D000047428",
                    "term": "Protein Kinase Inhibitors"
                },
                {
                    "id": "D000004791",
                    "term": "Enzyme Inhibitors"
                },
                {
                    "id": "D000045504",
                    "term": "Molecular Mechanisms of Pharmacological Action"
                }
            ],
            "browseLeaves": [
                {
                    "id": "M315",
                    "name": "Cetuximab",
                    "asFound": "Physician",
                    "relevance": "HIGH"
                },
                {
                    "id": "M218495",
                    "name": "Trametinib",
                    "asFound": "Surgery:",
                    "relevance": "HIGH"
                },
                {
                    "id": "M1346",
                    "name": "Antineoplastic Agents, Immunological",
                    "relevance": "LOW"
                },
                {
                    "id": "M25820",
                    "name": "Protein Kinase Inhibitors",
                    "relevance": "LOW"
                },
                {
                    "id": "M7951",
                    "name": "Enzyme Inhibitors",
                    "relevance": "LOW"
                }
            ],
            "browseBranches": [
                {
                    "abbrev": "ANeo",
                    "name": "Antineoplastic Agents"
                },
                {
                    "abbrev": "All",
                    "name": "All Drugs and Chemicals"
                }
            ]
        }
    },
    "hasResults": false
}